Deadline for abstract submission has now passed.
Please note that all tickets are now sold out.
This timely conference brings together the fundamental and clinical research communities working at the cutting edge of immuno-oncology interventions and their stratified application. Two and half days of stimulating sessions and debates, followed by parallel workshops on the last afternoon.
Abstract submissions offer the opportunity to present exciting new findings in poster sessions or as an invited short talk and is open to researchers at every career stage.
The meeting provides to all the speakers and delegates Continuing Professional Development (CPD) credits (Clinical Genetics, Haematology
Immunology and Medical Oncology).
This International Cancer Immunology Conference supported through the Cancer Research UK (CRUK) Centre Network and the Experimental Cancer Medicine Centres (ECMC) Network. Our intention is to bring together a broad cross-section of the community of researchers and clinicians working at the cutting edge of immune-oncology interventions and their stratified application. The conference will cover both the immediate and longer-term prospects in the development pipeline and the means through which we might better determine effective deployment of these interventions, including technology platforms and the ‘big data’ analytical hurdles.
Keynote speaker, Johns Hopkins, United States
Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins.
Oslo University, Norway
Our group aims to develop new T-cell based concepts for cancer immunotherapy that overcome the major challenge of self-tolerance in cancer. To this end, one of our main strategies involves studies of how the immune system from healthy donors can target patient cancer cells. We have a strong focus on the development of new technologies that allow high-throughput identification of therapeutic targets that can evoke immune responses, as lack of immunogenic targets represents a major limitation in therapeutic efficacy. The group furthermore has a strong translational focus and performs penetrating mechanistic analyses in clinical trials together with our clinical partners. The group is a member of K.G. Jebsen Center for Cancer Immunotherapy
Vanderbilt University, United States
Jonathan Irish is Assistant Professor in the Department of Cell & Developmental Biology (CDB) at Vanderbilt University, School of Medicine. He holds a secondary appointment in Pathology, Microbiology & Immunology (PMI) and is Scientific Director of the Cancer & Immunology Core (CIC) and the Mass Cytometry Center of Excellence (MCCE). Jonathan launched the Irish lab at Vanderbilt in 2012 after finishing his training with Garry Nolan (Ph.D.) and Ron Levy (Postdoc) at Stanford University.
King’s College London, UK
Sophie Papa is a Senior Lecturer and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust. Sophie undertook her medical training at the University of Oxford and Imperial College London. She completed a PhD in cancer immunotherapy from King’s College London in 2011. She is a clinical academic with research interests in the field of immune-oncology. Her research group studies approaches to optimise personalised cell based immune therapies for solid tumour oncology. In collaboration with colleagues at King’s Health Partners she is involved in delivering a first in man trial of CAR-T cell therapy for head and neck cancer. Sophie is a medical oncologist with a practice in malignant melanoma and is the lead for skin cancer research at Guy’s and St Thomas’ NHS Foundation Trust.
Abstract submission for participants
Abstract submission deadline: The deadline is now passed.
The conference will cover both the immediate and longer-term prospects in the development pipeline and the means through which we might better determine effective deployment of these interventions, including technology platforms and the ‘big data’ analytical hurdles.
The first day of the joint programme is the Experimental Cancer Medicine Centres (ECMC) national network day, designed to foster new links between lab immunology and early phase investigators.
The focus of the second day is the precision medicine and the role of cutting-edge omics in cancer immunology and immunotherapy.
“Big Data” in cancer immunology and potential clinical applications are the focuses of day 3. There will also be three optional hands-on workshops in the afternoon.
Bush House, 30 Aldwych, London, WC2B 4BG
Bush House is a Grade II listed building at the southern end of Kingsway between Aldwych and the Strand in London.
We have now moved staff and students into these new buildings, which provide a home for many of our academic departments, as well as state-of-the-art learning and social spaces and enhanced student facilities.
Bush House North & South Wings form the centre of Bush House buildings. The former home of the BBC World Service, they feature the iconic Kingsway portico entrance with its neoclassical columns and statues, as well as the building’s main lobby.